Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes

Cardiovascular Diabetology

Volumn 15, Issue 1, 2016, Pages

  van Giessen, Anoukh ^a,b   Boonman de Winter, Leandra J M ^a,c,d   Rutten, Frans H ^a   Cramer, Maarten J ^a   Landman, Marcel J ^e   Liem, Anho H ^f   Hoes, Arno W ^a   Koffijberg, Hendrik ^a,g  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Department of Scientific and Contract Research ^*  (Netherlands)

^d AMPHIA HOSPITAL   (Netherlands)

^e Cardiologist   (Netherlands)

^f SINT FRANCISCUS GASTHUIS   (Netherlands)

^g UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Cost effectiveness; Heart failure; Quality of life; Screening; Type 2 diabetes

Indexed keywords

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECHOCARDIOGRAPHY; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH CARE COST; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROBABILITY; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SYMPTOM; AGE; COMPARATIVE STUDY; COMPLICATION; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; ECONOMIC MODEL; ECONOMICS; ELECTRONIC HEALTH RECORD; MARKOV CHAIN; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; TIME FACTOR;

AGE FACTORS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTRONIC HEALTH RECORDS; FEMALE; HEALTH CARE COSTS; HEART FAILURE; HUMANS; MALE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; NETHERLANDS; PREDICTIVE VALUE OF TESTS; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS;

EID: 84962621216     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-016-0363-z     Document Type: Article

References (38)

1. Blendea MC, McFarlane SI, Isenovic ER, et al. Heart disease in diabetic patients. Curr Diab Rep. 2003;3(3):223-9.
2. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;14:803-69.
3. van Dieren S, Beulens JW, van der Schouw YT, et al. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010;17(Suppl 1):S3-8.
4. Abi KC, Roussel R, Mohammedi K, et al. Cause-specific mortality in diabetes: recent changes in trend mortality. Eur J Prev Cardiol. 2012;19(3):374-81.
5. Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55(8):2154-62.
6. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol. 2010;55(6):526-37.
7. Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. Early recognition of heart failure in patients with diabetes type 2 in primary care. A prospective diagnostic efficiency study. (UHFO-DM2). BMC Public Health. 2009;9:479.
8. Brooks R, Rabin R, de Charro F. The measurement and valuation of health status using EQ-5D: a European perspective. Faridabad: Kluwer Academic Publishers; 2002.
9. Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. Efficiently screening heart failure in patients with type 2 diabetes. Eur J Heart Fail. 2014;17:187-95.
10. Kelder JC, Cramer MJ, van WJ, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011;124(25):2865-73.
11. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-38.
12. Hoch JS, Dewa CS. A clinician's guide to correct cost-effectiveness analysis: think incremental not average. Can J Psychiatry. 2008;53(4):267-74.
13. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
14. The Criteria Committee of the New York Heart Association. Functional capacity and objective assessment. In: Dolgin M, editor. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston, MA: Little, Brown and Company, 1994. p. 253-5.
15. Statistics Netherlands (CBS). Lifetables Dutch population by age and sex, 2006-2010. 2012.
16. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle heart failure model: prediction of survival in heart failure. Circulation. 2006;113(11):1424-33.
17. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362(9386):777-81.
18. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767-71.
19. Palau P, Nunez E, Dominguez E, et al. Physical therapy in heart failure with preserved ejection fraction: a systematic review. Eur J Prev Cardiol. 2014;23:4-13.
20. Gommer AM, Poos MJJC. Heart failure: prevalence, incidence and mortality by age and sex [in Dutch]. Nationaal Kompas Volksgezondheid: Volksgezondheid Toekomst Verkenning; 2010.
21. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 1994;72(2 Suppl):S3-9.
22. Yao G, Freemantle N, Calvert MJ, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J. 2007;28(1):42-51.
23. Hoes AW, Voors AA, Rutten FH, et al. NHG-Standaard Hartfalen. Huisarts en Wetenschap. 2010;35(7):368-89.
24. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA et al. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties inde gezondheidszorg. College voor zorgverzekeringen. Geactualiseerde versie 2004. 2004.
25. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in degezondheidszorg. College voor zorgverzekeringen. Geactualiseerde versie 2010. 2010.
26. Dutch Healthcare Authority (NZA). Tariffs Dutch Healthcare. 2011.
27. College voor Zorgverzekeringen (CvZ)-The Health Care Insurance Board. Guidelines for pharmacoeconomic research. Updated version. Amstelveen: CvZ; 2006.
28. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456-67.
29. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338-45.
30. Chatterjee S, Moeller C, Shah N, et al. Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med. 2012;125(8):817-25.
31. Liu G, Zheng XX, Xu YL, et al. Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. Am J Cardiol. 2014;113(7):1198-204.
32. van Rosmalen J, de Kok IM, van Ballegooijen M. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG. 2012;119(6):699-709.
33. Senni M, Paulus WJ, Gavazzi A, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J. 2014;35(40):2797-815.
34. Gyberg V, De BD, De BG, et al. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovasc Diabetol. 2015;14:133.
35. Wang P, Huang R, Lu S, et al. HbA1c below 7% as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis. Cardiovasc Diabetol. 2015;14:124.
36. Jiao F, Fung CS, Wan YF, et al. Long-term effects of the multidisciplinary risk assessment and management program for patients with diabetes mellitus (RAMP-DM): a population-based cohort study. Cardiovasc Diabetol. 2015;14:105.
37. Ledwidge MT, O'Connell E, Gallagher J, et al. Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) study. Eur J Heart Fail. 2015;17(7):672-9.
38. National Institute for Public Health and the Environment (RIVM). Costs of diseases 2007 [in Dutch]. 2011. Report No.: 1.2.